Last reviewed · How we verify
Adenosine intravenous
Adenosine intravenous is a Small molecule drug developed by Haseki Training and Research Hospital. It is currently FDA-approved.
Adenosine intravenous is a marketed drug developed by Haseki Training and Research Hospital, positioned in the cardiovascular space. The key composition patent expires in 2028, providing a clear period of exclusivity. The primary risk is the lack of revenue data, which limits the ability to assess current market performance and potential competitive threats.
At a glance
| Generic name | Adenosine intravenous |
|---|---|
| Sponsor | Haseki Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine (PHASE1)
- Adenosine vs. Diltiazem (PHASE4)
- A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (PHASE3)
- Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System (NA)
- DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (PHASE3)
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adenosine intravenous CI brief — competitive landscape report
- Adenosine intravenous updates RSS · CI watch RSS
- Haseki Training and Research Hospital portfolio CI
Frequently asked questions about Adenosine intravenous
What is Adenosine intravenous?
Who makes Adenosine intravenous?
What development phase is Adenosine intravenous in?
Related
- Manufacturer: Haseki Training and Research Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing